Cipher Pharmaceuticals (CPH) investor relations material

Executive summary

• Q1 2026 net income rose 135% year-over-year to $6.2 million, with adjusted EBITDA up 25% to $7.7 million and revenue up 4% to $12.5 million, driven by strong U.S.-based Natroba business and stable Canadian portfolio.

• Four-pronged growth strategy: invest in Natroba, acquire/in-license complementary products, out-license Natroba globally, and pursue strategic company acquisitions.

• Launched a direct-to-consumer (DTC) sales model for Natroba in March 2026 to supplement existing channels; initial volumes low due to seasonality, with marketing ramp-up planned for Q2.

• Health Canada’s review for Natroba is underway, with a decision expected by end of 2026; commercialization in Canada pending approval.

• Focus remains on business development, including acquisitions, in-licensing, and maximizing cash flow.

Financial highlights

• Q1 2026 net revenue was $12.5 million, up 4% year-over-year, with licensing revenue up 52% to $1.1 million and Natroba product revenue up 3% to $6.9 million.

• Canadian product revenue was $4.5 million, down 2% year-over-year due to normalization after prior market share gains.

• Gross margin improved to 82% from 76% year-over-year, benefiting from higher licensing revenue and absence of prior year non-recurring inventory adjustments.

• Net income was $6.2 million ($0.24 per diluted share), up from $2.6 million ($0.10 per share) in Q1 2025.

• Adjusted EBITDA reached $7.7 million, a 25% increase year-over-year.

Outlook and guidance

• Focus on expanding Natroba’s reach via DTC and digital marketing, maximizing market share in North America, and pursuing business development opportunities.

• Expecting increased DTC volumes and higher net pricing as commercial sales grow.

• Health Canada’s decision on Natroba anticipated by year-end 2026.

• Plans to commercialize Natroba in Canada upon regulatory approval and pursue global out-licensing.